(Press-News.org) Crigler-Najjar syndrome is a rare autosomal recessive disorder caused by mutations in the UGT1A1 gene, which result in the toxic accumulation of bilirubin, a substance made by the liver in the body. Indeed, when the UDP-glucuronosyltransferase 1 isotype A1 (UGT1A1), the enzyme responsible for removing bilirubin, doesn't work, the substance accumulates, causing a severe and chronic jaundice, and becoming toxic for the brain and leading to lethality.
Gene therapy has allowed the restoration of an equivalent level of bilirubin to those found in healthy animals
Federico Mingozzi team (Généthon, Evry/France), in collaboration with the team of Andres Muro (ICGRB, Trieste/Italy) and the team of Piter Bosma (AMC, Amsterdam/Netherlands), transferred with an AAV vector (adeno-associated virus), developed by Généthon, a copy of the UGT1A1 gene (coding for the production of the UGT1A1 enzyme) in liver cells (hepatocytes) of rats and mice carriers of the anomaly. After injection, levels of bilirubin in the treated animals became equivalent to those of healthy animals. The correction was confirmed more than 6 months after gene therapy, without requiring prior immunosuppression or additional intervention.
The researchers demonstrated that a single injection of the AAV vector-UGT1A1 enabled the long-term correction of the Crigler-Najjar syndrome in the treated animals.
Towards a phase I/II clinical trial
These results open the way to the establishment of a phase I/II clinical trial by the end of 2016, of which Généthon will be the promoter. In 2015, regulatory toxicity studies and industrial transposition for the production of clinical batch processing under GMP (Good Manufacturing Practices) will take place at Généthon*. Twenty patients will be enrolled in 5 clinical centers in Europe: in France (APHP Antoine Béclère), the Netherlands (Academic Medical Center), Germany (Hannover Medical School), and Italy (Azienda Ospedale Papa Giovanni XXIII in Bergamo and Federico II Hospital in Naples).
Federico Mingozzi, driver for this work: "These promising results allowed us to start thinking about clinical trial, which hopefully will start by the end of 2016 or early 2017. I am very excited to continue this project, which finds its strength in all the participating actors - the researchers, the clinical investigators, and the patients' associations of France, Italy, and the Netherlands. Everyone has been working very hard together with the Genethon team since 2013."
Frédéric Revah, CEO of Généthon: "This new trial will be a new challenge for Généthon. Indeed, after undertaking the development of gene therapy treatments for immune deficiencies, for diseases of the muscle and contributing to the development of treatments for diseases of the vision and blood, Généthon will begin the development of a drug candidate targeting the liver. A new exciting project for Généthon and its unique expertise: develop and simultaneously produce gene therapy treatments for different families of orphan diseases."
These results were presented May 7, 2015 at the plenary session 10:30 (http://www.espghan2015.org/programme/).
The Crigler-Najjar syndrome
The Crigler-Najjar syndrome is an inherited disorder of bilirubin metabolism characterized by high serum levels of unconjugated hyperbilirubinemia due to hepatic deficit of bilirubin glucuronosyltransferase activity. Many mutations of UGT1A1 gene (2q37) are responsible for a partial or total loss of the activity of the enzyme, resulting in a more or less significant decrease in the conjugation of bilirubin. The complete absence of enzymatic activity of UGT1A1 causes the most severe form of Crigler-Najjar syndrome. Severe Crigler-Najjar patients survive only through very restrictive daily treatment by phototherapy (10 to 12 hours per day) or have to undergo liver transplantation. Milder forms of the disease, resulting from only a partial loss of UGT1A1 activity in liver, can be treated with phenobarbital alone or in combination with phototherapy.
The syndrome is characterized by an intense and chronic jaundice causing yellowing of the skin and of the the eyes. Jaundice can become toxic to the brain, causing severe neurological disorders that can lead to the death of patients. The disease is extremely rare with an annual incidence of 1/1 000 000 births.
INFORMATION:
About Généthon
Created by the AFM-Téléthon, Généthon's mission is to make available to patients innovative gene therapy treatments. Having played a pioneering role in deciphering the human genome, Généthon is today, with more than 200 scientists, physicians, engineers and regulatory affairs specialists, an international research and development center for preclinical and clinical gene therapy treatments for rare diseases. Généthon has the largest site in the world for GMP production of gene therapy products, Généthon Bioprod. In 2012, Généthon was the first associative laboratory to receive the 2012 Prix Galien for Pharmaceutical Research (France). As part of a therapeutic program on genetic diseases of the blood and immune system, Généthon working for over 10 years on gene therapy of Wiskott-Aldrich syndrome. The laboratory is currently conducting clinical trials for this disease in Europe, Paris and London, and the United States with the Children's Hospital Boston. *Généthon has one of the largest GMP production sites of gene therapy drugs in the world, Généthon Bioprod. In 2012, Généthon has received the prestigious Prix Galien for Pharmaceutical Research (France) and in 2015 Généthon was one of 16 winners of the Global Innovation Competition 2030 for its industrial process development work for vectors gene therapy.
Press Contacts:
Stéphanie Bardon / Gaëlle Monfort - 01 69 47 28 59 - presse@afm-telethon.fr
Luring longtime and new customers to try online shopping, and retaining them in a competitive and crowded marketplace, is the challenge of the day for established offline retailers. A study of the multichannel UK grocery shopping environment recently yielded insights that will be useful for retailers with an online channel or considering adding one to their customers' options.
A team of researchers from Belgium's KU Leuven (University of Leuven), led by doctoral candidate Kristina Melis, investigated purchasing behavior and the adoption of an online grocery shopping ...
Researchers at the University of Illinois at Chicago have determined the molecular structure of one of the proteins in the fine fibers of the brain plaques that are a hallmark of Alzheimer's disease. This molecule, called amyloid beta-42, is toxic to nerve cells and is believed to provoke the disease cascade.
The study is online in the journal Nature Structural and Molecular Biology.
Knowing the physical structure of the 42 amino acid-long form of amyloid beta in the fibers is key to understanding how it folds up improperly and aggregates into toxic plaques, says Yoshitaka ...
This news release is available in Spanish. (SACRAMENTO, Calif.) -- Researchers at UC Davis have developed a new intervention that identifies potentially depressed mothers and encourages them to seek treatment. The Motivating our Mothers (MOM) program takes a unique approach, relying on pediatricians rather than the mother's doctor for diagnosis. In the study, mothers were given a short survey to assess whether they needed additional care. Those who identified depression symptoms were then coached by a research assistant to seek further help.
The program had a remarkable ...
A new study shows that it is possible to use an imaging technique called cryo-electron microscopy (cryo-EM) to view, in near-atomic detail, the architecture of a metabolic enzyme bound to a drug that blocks its activity. This advance provides a new path for solving molecular structures that may revolutionize drug development, noted the researchers.
The protein imaged in this study was a small bacterial enzyme called beta-galactosidase; the drug to which it was bound is an inhibitor called phenylethyl-beta-D-thiogalactopyranoside (PETG), which fits into a pocket in the ...
Messenger RNA (mRNA) levels dictate most differences protein levels in fast-growing cells when analyzed using statistical methods that account for noise in the data, according to a new study by researchers from the University of Chicago and Harvard University.
The research, published May 7, 2015 in the journal PLOS Genetics, counters widely reported studies arguing that the correlation between mRNA transcript levels and protein levels is relatively low, and that processes acting after mRNA transcription override mRNA levels. Instead, the authors argue, these conclusions ...
Boston, MA -- Researchers at Harvard T. H. Chan School of Public Health and the Broad Institute have identified a protein on the surface of human red blood cells that serves as an essential entry point for invasion by the malaria parasite. The presence of this protein, called CD55, was found to be critical to the Plasmodium falciparum parasite's ability to attach itself to the red blood cell surface during invasion. This discovery opens up a promising new avenue for the development of therapies to treat and prevent malaria.
"Plasmodium falciparum malaria parasites have ...
Hereditary blindness caused by a progressive degeneration of the light-sensing cells in the eye, the photoreceptors, affects millions of people worldwide. Although the light-sensing cells are lost, cells in deeper layers of the retina, which normally cannot sense light, remain intact. A promising new therapeutic approach based on a technology termed "optogenetics" is to introduce light-sensing proteins into these surviving retinal cells, turning them into "replacement photoreceptors" and thereby restoring vision. However, several factors limit the feasibility of a clinical ...
PRINCETON, N.J.--The measles virus is known to cast a deadly shadow upon children by temporarily suppressing their immune systems. While this vulnerability was previously thought to have lasted a month or two, a new study shows that children may actually live in the immunological shadow of measles for up to three years - leaving them highly susceptible to a host of other deadly diseases.
Published in the journal Science, the study, led by researchers from Princeton University's Woodrow Wilson School of Public and International Affairs and Department of Ecology and Evolutionary ...
This news release is available in Spanish. Although the genetic blueprint of every cell is the same, each cell has the potential to become specific for a tissue or organ by controlling its gene expression. Thus, every cell "reads" or "switches on" a particular set of genes according to whether it should become a skin, heart, or liver cell. Launched by the National Institutes of Health (NIH) in 2010, the GTEx Project aims to create a reference database and tissue bank for scientists to study how genomic variants affect gene activity and disease susceptibility.
Following ...
CAMBRIDGE, Mass--Researchers have succeeded in creating a new "whispering gallery" effect for electrons in a sheet of graphene -- making it possible to precisely control a region that reflects electrons within the material. They say the accomplishment could provide a basic building block for new kinds of electronic lenses, as well as quantum-based devices that combine electronics and optics.
The new system uses a needle-like probe that forms the basis of present-day scanning tunneling microscopes (STM), enabling control of both the location and the size of the reflecting ...
